Feb 5 2010
Holdings Limited (ASX:BTA) today announced that it had received
written notification from GlaxoSmithKline that Relenza sales were $462
million and indicative royalties were $32.6 million, for the three
months ended 31 December 2009. The figures were calculated on an
Australian dollar exchange rate of 1.8182 to the UK pound, although the
actual payment will be calculated on exchange rates at 30 April 2010.
Biota will report first half indicative Relenza royalty income of $56.7
million (2008: $3.8m) when it releases its Interim Report on 17 February
2010.